[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622468":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":29,"id":55,"slug":29,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":29,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":29,"enrollmentInfo":63,"targetDuration":29,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":38,"whyStopped":29,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Rambam Health Care Campus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Chronic metamizole users","EXPERIMENTAL","Patients receiving Optalgin prior to study enrollment",[13],"Drug: metamizole",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2: New metamizole users","Patients receiving Optalgin after to study enrollment",[13],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","metamizole","chronic metamizole use",[9,15],[25],"OPTALGIN",{"type":20,"name":21,"description":27,"armGroupLabels":28,"otherNames":29},"New metamizole users",[9,15],null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Liat Rappaport","CONTACT","+97247776234","o_trials@rambam.health.gov.il",[37],{"facility":5,"status":38,"city":39,"state":29,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Haifa","31096","Israel","IL",{"type":44,"coordinates":45},"Point",[46,47],34.99928,32.81303,{"lat":47,"lon":46},[50],{"name":29,"role":33,"phone":51,"phoneExt":29,"email":52},"047776724","g_froumin@rambam.health.gov.il",{"type":54,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100622468",false,"NCT07384013","Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Inclusion Criteria:\n\n* Adult oncology patients (≥18 years old).\n* Receiving apixaban or rivaroxaban for anticoagulation.\n* New\u002Fcurrent metamizole users taking at least 1g TID for pain management.\n* Platelets ≥100×10⁹\u002FL\n* ECOG PS\\\u003C3\n* Provided informed consent\n\nExclusion Criteria:\n\n* History of allergic reaction to metamizole or DOACs.\n* Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT\u002Fzonda)","ALL","18 Years",{"count":64,"type":65},30,"ESTIMATED","INTERVENTIONAL",[68],"NA","Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)",[71,72,73],"Oncologic Diseases","Coagulation Defect","Pain Management",[75,76],"Direct Oral Anticoagulants (DOACs)","Optalgin","2026-01-26",{"date":79,"type":80},"2026-02-03","ACTUAL",{"date":82,"type":80},"2025-11-01",{"date":84,"type":65},"2027-12-31",{"name":5,"class":6},1]